Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers.

Published in: PLoS biology (2023)

Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways. A new study in PLOS Biology demonstrates that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard therapies.

Keyphrases

dna methylation
gene expression
prostate cancer
long non coding rna
long noncoding rna
stem cells
transcription factor
binding protein
cancer therapy
young adults